Edgewise Therapeutics (EWTX) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Vaxcyte (PCVX) over the past year, gaining 155.6% versus a gain of 59.6%. Over five years, PCVX leads with a +166.3% price change compared with +121.1% for EWTX. Vaxcyte is the larger company by market cap ($9.67 billion vs $4.26 billion), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | PCVX |
|---|---|---|
| Share price | $39.23 | $65.02 |
| Market cap | $4.26B | $9.67B |
| 1-day change | -0.86% | -2.90% |
| YTD return | +58.09% | +40.91% |
| 1-year return | +155.57% | +59.59% |
| 5-year return | +121.14% | +166.35% |
| EPS (TTM) | $-1.85 | $-7.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-167.79M | $-766.63M |
| 52-week high | $48.51 | $90.75 |
| 52-week low | $14.25 | $39.87 |
| Distance from 52-week high | -19.13% | -28.36% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +34.13% | +79.96% |
| Average volume | 1.34M | 1.66M |
| Shares outstanding | 108.60M | 148.81M |
| Employees | 127 | 507 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vaxcyte is about 2.3 times larger than Edgewise Therapeutics by market value ($9.67B vs $4.26B).
- EWTX has outperformed PCVX by 96.0 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Healthcare · Biotechnology · 127 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Healthcare · Biotechnology · 507 employees
EWTX vs PCVX FAQ
Which is bigger, Edgewise Therapeutics or Vaxcyte?
Vaxcyte (PCVX) is larger, with a market capitalization of $9.67B compared with $4.26B for Edgewise Therapeutics (EWTX).
Which stock has performed better over the past year, EWTX or PCVX?
EWTX returned +155.57% over the past 12 months, compared with +59.59% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.